The cytochrome P450 2D6 (CYP2D6) genotype is the single most important determinant of
CYP2D6 activity as well as interindividual and interpopulation variability in CYP2D6 activity …

Background Quantitative predictions of in vivo drug-drug interactions (DDIs) resulting from
metabolic inhibition are commonly made based upon the inhibitor concentration at the …

Abstract Cytochrome P450 (CYP) 2C19 is essential for the metabolism of clinically used
drugs including omeprazole, proguanil, and S-mephenytoin. This hepatic enzyme exhibits …

Background: To investigate whether the pharmacodynamics and pharmacokinetics of
omeprazole (OPZ) are dependent of the CYP2C19 genotype status in Chinese people …

Aims To evaluate the reliability of the omeprazole hydroxylation index as a marker for
polymorphic CYP2C19 activity in a Japanese population of healthy young subjects (n= 78) …

Introduction and objective Polymorphisms in genes encoding drug metabolizing enzymes
may lead to varied enzyme activity and inter-individual variability in drug efficacy and/or …

We propose a framework to enable quantitative prediction of the impact of CYP2D6
polymorphisms on drug exposure. It relies mostly on in vivo data and uses two characteristic …

First pass metabolism in the intestinal mucosa is a determinant of oral bioavailability of
CYP3A substrates and so the prediction of intestinal availability (Fg) of potential drug …

Drug-drug interactions (DDI) and genomic variation (PG) can lead to dangerously high
blood and tissue concentrations with some drugs but may be negligible with other drugs …

This work provides a perspective on the qualification and verification of physiologically
based pharmacokinetic (PBPK) platforms/models intended for regulatory submission based …